ProMIS Accounts Payable from 2010 to 2025
| PMN Stock | USD 0.93 0 0.29% |
Accounts Payable | First Reported 2005-06-30 | Previous Quarter 2 M | Current Value 1.6 M | Quarterly Volatility 2.2 M |
Check ProMIS Neurosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProMIS Neurosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 46.1 K, Total Revenue of 0.0 or Other Operating Expenses of 22.8 M, as well as many indicators such as Price To Sales Ratio of 5.1 K, Dividend Yield of 0.0 or PTB Ratio of 3.11. ProMIS financial statements analysis is a perfect complement when working with ProMIS Neurosciences Valuation or Volatility modules.
ProMIS | Accounts Payable |
Latest ProMIS Neurosciences' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of ProMIS Neurosciences over the last few years. An accounting item on the balance sheet that represents ProMIS Neurosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of ProMIS Neurosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. ProMIS Neurosciences' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProMIS Neurosciences' overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
ProMIS Accounts Payable Regression Statistics
| Arithmetic Mean | 2,709,150 | |
| Geometric Mean | 908,371 | |
| Coefficient Of Variation | 165.74 | |
| Mean Deviation | 3,378,708 | |
| Median | 492,775 | |
| Standard Deviation | 4,490,025 | |
| Sample Variance | 20.2T | |
| Range | 12.3M | |
| R-Value | 0.72 | |
| Mean Square Error | 10.3T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 683,639 | |
| Total Sum of Squares | 302.4T |
ProMIS Accounts Payable History
About ProMIS Neurosciences Financial Statements
ProMIS Neurosciences investors utilize fundamental indicators, such as Accounts Payable, to predict how ProMIS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 12 M | 12.5 M |
Pair Trading with ProMIS Neurosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.Moving against ProMIS Stock
| 0.36 | GILD | Gilead Sciences Sell-off Trend | PairCorr |
| 0.35 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of ProMIS Neurosciences Correlation against competitors. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.